Inclusion Criteria

DISEASE CHARACTERISTICS:

- Patients who have elected to undergo, or who have undergone (within 8 weeks) a
surgical procedure that results (at minimum) in the absence of both ovaries

- Patients enrolled in the screening arm of GOG-0199 who decide to undergo surgery
are potentially eligible for GOG-0215

- Baseline bone mass density (BMD) T-Score ≥ -1.5 (no more than 1.5 standard deviation
below the mean value for young adults) on both the total lumbar spine (L1-L4 region,
not individual bones) and bilateral hip

- Patients who had/have at least 1 intact ovary at the time of surgery are eligible

- No prior distant metastatic malignant disease within the past 5 years

- Patients treated for stage M1 (any T, any N) diagnosis in the past 5 years are
ineligible

- Patients who achieved a complete response after treatment for rM0 (any T, any N)
within the past 5 years are eligible

PATIENT CHARACTERISTICS:

- Premenopausal*

- Last menstrual cycle occurred < 12 months prior to study enrollment NOTE: *In
unclear cases premenopausal status may be determined by follicle stimulating
hormone level AND must be ≤ 20 U/L

- GOG performance status 0-2

- Creatinine clearance > 60 mL/min

- No clinical or radiological evidence of existing fracture of the lumbar spine or
bilateral hip

- No history of hip of spine fracture with low-intensity trauma or not associated with
trauma

- No uncontrolled seizure disorder associated with falls

- No diseases that influence bone metabolism, including any of the following:

- Paget's disease

- Osteogenesis imperfecta

- Uncontrolled thyroid or parathyroid dysfunction within 12 months prior to study
entry

- No other nonmalignant systemic disease, including any of the following:

- Uncontrolled infection

- Uncontrolled type 2 diabetes mellitus

- Cardiovascular, renal, hepatic, or lung disease that would prevent prolonged
follow-up

- History of thrombosis or thromboembolism allowed

- No known HIV positivity

- No known hypersensitivity to zoledronate or other bisphosphonates

- No psychiatric, psychological, or other conditions that prevent fully informed
consent

- No other active malignancy except nonmelanoma skin cancer

- No history of any medical condition that places the patient at risk for donating
blood for research purposes (e.g., chronic infectious diseases, sever anemia, or
hemophilia)

- Not pregnant

- Negative pregnancy test

- No current active dental problems, including any of the following:

- Infection of the teeth or jawbone (maxilla or mandible)

- Dental or fixture trauma

- Current or prior diagnosis of osteonecrosis of the jaw

- Exposed bone in the mouth

- Slow healing after dental procedures

PRIOR CONCURRENT THERAPY:

- No recent (within 6 weeks) or planned dental or jaw surgery (e.g., extraction or
implants)

- No prior treatment for osteoporosis

- No adjuvant radiotherapy within the past 31 days

- No chemotherapy within the past 30 days

- No prior surgery to the hip or spine

- No prior systemic sodium fluoride for > 3 months during the past 2 years

- No more than 30 days use in the past 12 months and no concurrent tamoxifen,
raloxifene, or any other selective estrogen-receptor modulator (SERM)

- More than 12 months since prior and no concurrent endocrine therapy

- Insulin and/or oral antidiabetic medications allowed

- Thyroid hormone replacement allowed

- More than 12 months since prior and no concurrent estrogen or hormone replacement
therapy (estrogen plus progesterone or estrogen alone)

- Prior or concurrent oral contraceptives allowed

- Systemic (oral) hormone replacement therapy following surgery not allowed

- Vaginal (non-systemic) estrogen allowed

- More than 12 months since prior and no concurrent oral or IV bisphosphonate

- More than 12 months since prior and no concurrent anabolic steroids or growth hormone

- More than 12 months since prior and no concurrent systemic corticosteroids

- Concurrent short term corticosteroid therapy (to prevent/treat
chemotherapy-induced nausea/vomiting) allowed

- More than 6 months since prior and no concurrent Tibolone

- More than 2 weeks since prior and no concurrent drugs known to affect the skeleton
(e.g., calcitonin, mithramycin, or gallium nitrate)

- No concurrent chemotherapy or radiotherapy

- No concurrent aromatase inhibitors

- Concurrent enrollment on protocol GOG-0199 allowed